|
WO2021030193A1
|
|
System and method for classifying genomic data
|
|
WO2021030030A1
|
|
Machine methods to determine neoepitope payload toxicity
|
|
WO2021016545A1
|
|
Immunome profiling for engineering white blood cells
|
|
WO2021034444A1
|
|
Genomic-driven targeted therapies
|
|
WO2020219165A1
|
|
Weakly supervised learning with whole slide images
|
|
WO2020185411A1
|
|
System and method for variant calling
|
|
KR20200087702A
|
|
Srm/mrm assays for molecular profiling tumor tissue
|
|
KR20200087701A
|
|
Srm and dia assays for clinical cancer evaluation
|
|
KR20200087700A
|
|
Evaluating sdhb protein expression by mass spectrometry
|
|
WO2020118053A1
|
|
Omics detection of nonhomologous end joining repair site signatures
|
|
WO2020117853A1
|
|
Methods of making therapeutic t lymphocytes
|
|
WO2020102670A1
|
|
Classification based on characterization analysis methods and systems
|
|
WO2020092613A1
|
|
Methods for predicting response to temozolomide therapy for patients with colon cancer
|
|
WO2020092589A1
|
|
Immune checkpoint therapeutic methods
|
|
WO2020092101A1
|
|
Consensus molecular subtypes sidedness classification
|
|
WO2020092038A1
|
|
Cdkn2a screening germline expression
|
|
WO2020077128A1
|
|
Tumor hla mutation versus matched normal hla
|
|
WO2020073007A1
|
|
Molecular microbiome profiling for wound healing
|
|
WO2020091944A1
|
|
Genomic and immune infiltration differences between msi and mss gi tumors
|
|
WO2020072223A1
|
|
Evidence based selection of patients for clinical trials using histopathology
|
